ArticleInflammatory bowel diseases2021
Prevalence and Risk Factors of Substance Use Disorder in Inflammatory Bowel Disease.
Article in Inflammatory bowel diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 20 citations in OpenAlex.
- Trends in Use of Prescribed Opioids in Incident and Prevalent Patients With Ulcerative Colitis: A Nationwide Study in Sweden.Inflammatory bowel diseases · 2026Article
- Predictors of Stress, Anxiety, Depression and Quality of Life in Patients Diagnosed with Chronic Inflammatory Bowel Disease in Romania: A Cross-Section Observational Case-Report Study.Journal of clinical medicine · 2026Article
- Higher Prescribed Opioid Use Among Adults With Crohn's Disease Than General Population: A Nationwide Cohort Study in Sweden 2006-2021.Alimentary pharmacology & therapeutics · 2025Article
- The Spectrum of Psychiatric Comorbidity in Individuals With Inflammatory Bowel Disease.Crohn's & colitis 360 · 2025Article
- Lifestyle Factors and Silent Inflammatory Bowel Disease.Inflammatory intestinal diseases · 2023Article
- Lifestyle Factors Associated with Abdominal Pain in Quiescent Inflammatory Bowel Disease.Digestive diseases and sciences · 2023Article
- Abdominal Pain in Inflammatory Bowel Disease: An Evidence-Based, Multidisciplinary Review.Crohn's & colitis 360 · 2023Article
- Trends in hospital admissions and mortality among inflammatory bowel disease patients with substance use disorder: a 10-year United States nationwide analysis.Proceedings (Baylor University. Medical Center) · 2023Article
- Causal association between inflammatory bowel disease and hidradenitis suppurativa: A two-sample bidirectional Mendelian randomization study.Frontiers in immunology · 2023Article
- Article
- Prevalence and Risk Factors of Substance Use Disorder in Rheumatoid Arthritis.ACR open rheumatology · 2021Article
- Polysubstance use in inflammatory bowel disease.Journal of digestive diseases · 2021Article
- Association Between Inflammatory Bowel Disease and Psychiatric Morbidity and Suicide: A Swedish Nationwide Population-Based Cohort Study With Sibling Comparisons.Journal of Crohn's & colitis · 2021Article
- Emerging Comorbidities in Inflammatory Bowel Disease: Eating Disorders, Alcohol and Narcotics Misuse.Journal of clinical medicine · 2021Review
- Polysubstance use in inflammatory bowel disease is associated with increased risk of emergency department visits: a longitudinal study.Annals of gastroenterologyArticle
- Substance abuse and inpatient outcomes in inflammatory bowel disease hospitalizations in the United States: a propensity matched analysis.Annals of gastroenterologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 2 countries.
Funding
Abstract
backgroundSubstance use disorders (SUDs) impose a substantial individual and societal burden; however, the prevalence and associated factors in persons with inflammatory bowel disease (IBD) are largely unknown. We evaluated the prevalence and risk factors of SUD in an IBD cohort.
methodsInflammatory bowel disease participants (n = 247) were recruited via hospital- and community-based gastroenterology clinics, a population-based IBD research registry, and primary care providers as part of a larger cohort study of psychiatric comorbidity in immune-mediated inflammatory diseases. The Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders IV was administered to participants to identify lifetime SUD, anxiety disorder, and major depressive disorder. Additional questionnaires regarding participants' sociodemographic and clinical characteristics were also completed. We examined demographic and clinical factors associated with lifetime SUD using unadjusted and adjusted logistic regression modeling.
resultsForty-one (16.6%) IBD participants met the criteria for a lifetime diagnosis of an SUD. Factors associated with elevated odds of SUD were ever smoking (adjusted odds ratio [aOR], 2.96; 95% confidence interval [CI], 1.17-7.50), male sex (aOR, 2.44; 95% CI, 1.11-5.36), lifetime anxiety disorder (aOR, 2.41; 95% CI, 1.08-5.37), and higher pain impact (aOR, 1.08; 95% CI, 1.01-1.16).
conclusionsOne in six persons with IBD experienced an SUD, suggesting that clinicians should maintain high index of suspicion regarding possible SUD, and inquiries about substance use should be a part of care for IBD patients, particularly for men, smokers, and patients with anxiety disorders and pain.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.